Percutaneous transaxillary approach (PTAX) through the first segment of the axillary artery is not widely recognized as a safe method. Furthermore, PTAX has never been directly compared between ...
DANVERS, Mass., Abiomed, Inc. a leading provider of breakthrough heart recovery and support technologies, announced today that the Impella 5.5™ heart pump received CE marking1 approval in Europe and ...
DANVERS, Mass.--(BUSINESS WIRE)--Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s (NASDAQ: ...
For circulatory support in cardiogenic shock, the best choice between Impella and intra-aortic balloon pump (IABP) has been controversial. Now, new data is complicating the debate. Presenting at the ...
DANVERS, Mass.-Abiomed announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The expansion extends the duration of ...
Abiomed’s, a leading provider of breakthrough heart recovery and support technologies, newest heart pump, the Impella 5.5 with SmartAssist, has received US Food and Drug Administration (FDA) ...
The US Food and Drug Administration (FDA)-approved labeling for the Impella 5.0 and Impella LD heart pumps (Abiomed) has been expanded to allow for longer support time in critically ill patients, the ...
NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results